An amino-bisphosphonate targets MMP-9 - Expressing macrophages and angiogenesis to impair cervical carcinogenesis

Journal of Clinical Investigation

Volumn 114, Issue 5, 2004, Pages 623-633

  Giraudo, Enrico ^a   Inoue, Masahiro ^a,b   Hanahan, Douglas ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; GELATINASE B; VASCULOTROPIN; ZOLEDRONIC ACID; ANGIOGENESIS INHIBITOR; IMIDAZOLE DERIVATIVE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEMALE; GENE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN PAPILLOMAVIRUS TYPE 16; KNOCKOUT GENE; KNOCKOUT MOUSE; MACROPHAGE; MMP9 GENE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PHENOTYPE; PRECANCER; PRIORITY JOURNAL; RECEPTOR AFFINITY; STROMA; TUMOR GROWTH; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VIRUS ONCOGENE; WART VIRUS; ANIMAL; CELL MOTION; DRUG ANTAGONISM; ENZYME ACTIVATION; ENZYMOLOGY; GENETICS; HUMAN; MACROPHAGE ACTIVATION; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TRANSGENIC MOUSE; UTERINE CERVIX TUMOR; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL MOVEMENT; CERVICAL INTRAEPITHELIAL NEOPLASIA; DIPHOSPHONATES; ENZYME ACTIVATION; FEMALE; HUMANS; IMIDAZOLES; MACROPHAGE ACTIVATION; MACROPHAGES; MATRIX METALLOPROTEINASE 9; MICE; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; UTERINE CERVICAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 4944239035     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200422087     Document Type: Article

References (63)

1. Waggoner, S.E. 2003. Cervical cancer. Lancet. 361:2217-2225.
2. Clifford, G.M., Smith, J.S., Plummer, M., Munoz, N., and Franceschi, S. 2003. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer. 88:63-73.
3. Smith-McCune, K.K., and Weidner, N. 1994. Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res. 54:800-804.
4. Smith-McCune, K., Zhu, Y.H., Hanahan, D., and Arbeit, J. 1997. Cross-species comparison of angiogenesis during the premalignant stages of squamous carcinogenesis in the human cervix and K14-HPV16 transgenic mice. Cancer Res. 57:1294-1300.
5. Dobbs, S.P., Hewett, P.W., Johnson, I.R., Carmichael, J., and Murray, J.C. 1997. Angiogenesis is associated with vascular endothelial growth factor expression in cervical intraepithelial neoplasia. Br. J. Cancer. 76:1410-1415.
6. Guidi, A.J., et al. 1995. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J. Natl. Cancer Inst. 87:1237-1245.
7. Van Trappen, P.O., et al. 2002. A model for co-expression pattern analysis of genes implicated in angiogenesis and tumour cell invasion in cervical cancer. Br. J. Cancer. 87:537-544.
8. Asha Nair, S., Karunagaran, D., Nair, M.B., and Sudhakaran, P.R. 2003. Changes in matrix metalloproteinases and their endogenous inhibitors during tumor progression in the uterine cervix. J. Cancer Res. Clin. Oncol. 129:123-131.
9. Arbeit, J.M., Munger, K., Howley, P.M., and Hanahan, D. 1994. Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J. Virol. 68:4358-4368.
10. Coussens, L.M., Hanahan, D., and Arbeit, J.M. 1996. Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. Am. J. Pathol. 149:1899-1917.
11. Arbeit, J.M., Howley, P.M., and Hanahan, D. 1996. Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 93:2930-2935.
12. Elson, D.A., et al. 2000. Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis. Cancer Res. 60:1267-1275.
13. Bergers, G., et al. 2000. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2:737-744.
14. Bergers, G., and Benjamin, L.E. 2003. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer. 3:401-410.
15. Brekken, R.A., Huang, X., King, S.W., and Thorpe, P.E. 1998. Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res. 58:1952-1959.
16. Hiratsuka, S., et al. 2002. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell. 2:289-300.
17. Coussens, L.M., Tinkle, C.L, Hanahan, D., and Werb, Z. 2000. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell. 103:481-490.
18. Coussens, L.M., et al. 1999. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 13:1382-1397.
19. Rodriguez-Manzaneque, J.C., et al. 2001. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc. Natl. Acad. Sci. U. S. A. 98:12485-12490.
20. Heissig, B., Hattori, K., Friedrich, M., Rafii, S., and Werb, Z. 2003. Angiogenesis: vascular remodeling of the extracellular matrix involves metalloproteinases. Curr. Opin. Hematol. 10:136-141.
21. Belotti, D., et al. 2003. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res. 63:5224-5229.
22. Bergers, G., Javaherian, K., Lo, K.M., Folkman, J., and Hanahan, D. 1999. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 284:808-812.
23. Coussens, L.M., Fingleton, B., and Matrisian, L.M. 2002. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 295:2387-2392.
24. Cohen, M.H., et al. 2002. U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid. Oncologist. 7:393-400.
25. Ibrahim, A., et al. 2003. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin. Cancer Res. 9:2394-2399.
26. Wood, J., et al. 2002. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J. Pharmacol. Exp. Ther. 302:1055-1061.
27. Fournier, P., et al. 2002. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 62:6538-6544.
28. Hamma-Kourbali, Y., et al. 2003. A novel non-containing-nitrogen bisphosphonate inhibits both in vitro and in vivo angiogenesis. Biochem. Biophys. Res. Commun. 310:816-823.
29. Sebbah-Louriki, M., et al. 2002. A new phenylacetate-bisphosphonate inhibits breast cancer cell growth by proapoptotic and antiangiogenic effects. Anticancer Res. 22:3925-3931.
30. Boissier, S., et al. 2000. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 60:2949-2954.
31. Teronen, O., et al. 1999. MMP inhibition and downregulation by bisphosphonates. Ann. N. Y. Acad. Sci. 878:453-465.
32. Frith, J.C., and Rogers, M.J. 2003. Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro. J. Bone Miner. Res. 18:204-212.
33. Luckman, S.P., et al. 1998. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 13:581-589.
34. Itoh, T., et al. 1998. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 58:1048-1051.
35. Vu, T.H., et al. 1998. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell. 93:411-422.
36. Davidson, B., et al. 1999. Expression of matrix metalloproteinase-9 in squamous cell carcinoma of the uterine cervix-clinico pathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol. Oncol. 72:380-386.
37. Sheu, B.C., et al. 2003. Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. Cancer Res. 63:6537-6542.
38. Oades, G.M., Senaratne, S.G., Clarke, I.A., Kirby, R.S., and Colston, K.W. 2003. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J. Urol. 170:246-252.
39. Green, J.R. 2003. Antitumor effects of bisphosphonates. Cancer. 97:840-847.
40. Benford, H.L., McGowan, N.W., Helfrich, M.H., Nuttall, M.E., and Rogers, M.J. 2001. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone. 28:465-473.
41. Valleala, H., et al. 2003. Regulation of MMP-9 (gelatinase B) in activated human monocyte/ macrophages by two different types of bisphosphonates. Life Sci. 73:2413-2420.
42. Boyle, W.J., Simonet, W.S., and Lacey, D.L. 2003. Osteoclast differentiation and activation. Nature. 423:337-342.
43. Khapli, S.M., Mangashetti, L.S., Yogesha, S.D., and Wani, M.R. 2003. IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage. J. Immunol. 171:142-151.
44. Rogers, M.J., et al. 2000. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 88:2961-2978.
45. Nguyen, M., Arkell, J., and Jackson, C.J. 2001. Human endothelial gelatinases and angiogenesis. Int. J. Biochem. Cell Biol. 33:960-970.
46. Hahn-Dantona, E., et al. 1999. Activation of proMMP-9 by a plasmin/MMP-3 cascade in a tumor cell model. Regulation by tissue inhibitors of metalloproteinases. Ann. N. Y. Acad. Sci. 878:372-387.
47. Zhao, Y.G., et al. 2003. Activation of pro-gelatinase B by endometase/matrilysin-2 promotes invasion of human prostate cancer cells. J. Biol. Chem. 278:15056-15064.
48. Visse, R., and Nagase, H. 2003. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 92:827-839.
49. Bezzi, M., Hasmim, M., Bieler, G., Dormond, O., and Ruegg, C. 2003. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J. Biol. Chem. 278:43603-43614.
50. Heissig, B., et al. 2002. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell. 109:625-637.
51. Rabbany, S.Y., Heissig, B., Hattori, K., and Rafii, S. 2003. Molecular pathways regulating mobilization of marrow-derived stem cells for tissue revascularization. Trends Mol. Med. 9:109-117.
52. Senaratne, S.G., Mansi, J.L., and Colston, K.W. 2002. The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells. Br. J. Cancer. 86:1479-1486.
53. Corey, E., et al. 2003. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin. Cancer Res. 9:295-306.
54. Hamano, Y., et al. 2003. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell. 3:589-601.
55. Hanahan, D., Bergers, G., and Bergsland, E. 2000. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 105:1045-1047.
56. Bergers, G., and Hanahan, D. 2002. Combining antiangiogenic agents with metronomic chemotherapy enhances efficacy against late-stage pancreatic islet carcinomas in mice. Cold Spring Harb. Symp. Quant. Biol. 67:293-300.
57. Engleman, M.A., and Small, W., Jr. 2003. Combined modality therapy in the treatment of gynecologic malignancies. Semin. Oncol. 30:80-94.
58. Pollard, J.W. 2004. Opinion: Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer. 4:71-78.
59. Huang, S., et al. 2002. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J. Natl. Cancer Inst. 94:1134-1142.
60. Riley, R.R., et al. 2003. Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res. 63:4862-4871.
61. Behrendtsen, O., Alexander, C.M., and Werb, Z. 1992. Metalloproteinases mediate extracellular matrix degradation by cells from mouse blastocyst outgrowths. Development. 114:447-456.
62. Lopez, T., and Hanahan, D. 2002. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell. 1:339-353.
63. Rhee, J.S., Diaz, R., Korets, L., Hodgson, J.G., and Coussens, L.M. 2004. TIMP-1 alters susceptibility to carcinogenesis. Cancer Res. 64:952-961.